Tianlong, an innovative high-tech company specialising in molecular diagnostic products in China, has partnered with public hospitals in northern Thailand to build up detection measures for hepatitis C (HCV) and hepatitis B (HBV), and for the early diagnosis and treatment of the viruses.

Globally, more than 350 million people are living with viral hepatitis, and 9 in ten people living with hepatitis are unaware of their diagnosis. Tianlong's HCV&HBV detection solution can help reduce the transmission of the disease by enabling early diagnosis and proper treatment.

Since October 2022, Tianlong's HCV&HBV detection solution has been successfully installed in public hospitals in Thailand. The company has reached a 7-year agreement with local hospitals, and its solution will be seen in more local hospitals in the future.

Tianlong's HCV&HBV reagents, compatible with its nucleic acid extractor PANA9600S and PCR system Gentier 96, provide a rapid test with high sensitivity, which has received great praise from high-end users.

Tianlong's STIs solutions will also be applied in Thailand soon to help prevent and control sexually transmitted infections (STIs).